SAN DIEGO, CA, March 22, 2022 (GLOBE NEWSWIRE) --

via NewMediaWire --Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”) (“Sigyn Therapeutics” or the “Company”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis and other life-threatening disorders, announced today that it has filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") and provided a corporate update. The Company’s Sigyn Therapy™ is a novel blood purification technology designed to perform functions that are beyond the reach of drugs and overcome the limitations of current devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide.

“2021 was a transformative year, during which we advanced Sigyn Therapy from conceptual design to clinical application and added key members to our clinical and management team,” stated Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “During the year, we conducted a series of studies that validated Sigyn Therapy’s potential to address an unrivaled breadth of therapeutics targets. Moving forward, we will seek to demonstrate that our expansive capabilities translate into patient benefit through human clinical studies.”

Sigyn Therapeutics plans to incorporate results from recent in vivo and in vitro studies into an Investigational Device Exemption that the Company is drafting for submission to the U.S. Food and Drug Administration to support the advancement of human clinical studies.

2021 and Recent Development Program Milestone Achievements

In January 2021, announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy to address CytoVesicles (extracellular vesicles that transport inflammatory cargos in the bloodstream). Prior to this milestone event, the Company reported the simultaneous elimination of endotoxin and relevant pro-inflammatory cytokines from human blood plasma in December 2020.

In April 2021, disclosed initial in vitro study observations that demonstrated the ability of Sigyn Therapy to adsorb viral pathogens, including SARS-CoV-2 (COVID-19).

In July 2021, announced the completion of an in vitro blood purification study that demonstrated the broad-spectrum ability of Sigyn Therapy to eliminate hepatic toxins (ammonia, bile acid & bilirubin) associated with Hepatic Encephalopathy (“HE”), a life-threatening neurological disorder that often occurs in individuals suffering from chronic and acute forms of liver failure.

In July 2021, disclosed the completion of the first-in-mammal pilot animal study that validated the feasibility of a clinical protocol that resulted in the safe administration of Sigyn Therapy during six-hour treatment exposures.

In December 2021, announced that preclinical in vitro studies had validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma.

In February 2022, reported the successful completion of an in vivo animal study conducted at the University of Michigan, which demonstrated Sigyn Therapy to be safe and well tolerated. A video of Sigyn Therapy being administered on January 7, 2022 can be accessed here.

In January 2021, appointed industry veteran Eric Lynam as Head of Clinical Affairs, with a mandate to oversee clinical studies of Sigyn Therapy.

In April 2021, appointed former Aethlon Medical executive Charlene Owen as Director of Operations.

In March 2022, appointed accomplished financial executive, Jeremy Ferrell, CPA, MBA as Chief Financial Officer, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping to manage the Company’s relationships and interactions with the investment community.

In March 2022, announced the appointments of two internationally recognized clinician researchers, Alexander S. Yevzlin, MD, FASN and H. David Humes, MD, to Sigyn Therapeutics’ Scientific Advisory Board.

For the year ended December 31, 2021, the Company had a loss from operations of approximately $2.0 million, compared to an operating loss of approximately $916,000 for the comparable period of 2020. The Company’s net loss for the year ended December 31, 2021 was approximately $3.0 million, or approximately $0.08 per share, compared to a net loss of approximately $1.3 million, or approximately $0.17 per share, for the comparable period in 2020. In 2021, net cash used in operating activities was approximately $1.8 million.

A copy of Sigyn Therapeutics’ annual report is available on the SEC's website at www.sec.gov, and on the Company's website at www.sigyntherapeutics.com under "Financial Info" in the Investors section.

Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide. Sigyn Therapy™ is a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream.

Beyond establishing a novel strategy to combat sepsis, candidate treatment indications for Sigyn Therapy include, but are not limited to; emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases.

To learn more, visit www.SigynTherapeutics.com.

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Stephen Kilmer Sigyn Therapeutics, Inc. Investor Relations (646) 274-3580 stephen@sigyntherapeutics.com

Russo Partners, LLC David Schull (212) 845-4271 David.Schull@russopartnersllc.com

Nic Johnson (212) 845-4242 Nic.Johnson@russopartnersllc.com

Yahoo Finance anchor Dave Briggs looks at how cannabis stocks are performing after legalization passes the House of Representatives.

An important U.S. regulator raises concerns about 'fraudulent and manipulative acts and practices.'

(Bloomberg) -- U.S. President Joe Biden’s plan to tackle record gasoline prices with an unprecedented release of emergency oil reserves may stifle domestic crude drilling just when it’s needed most. Most Read from BloombergUkraine Update: Russia Says Kyiv Makes Rare Cross-Border StrikeNever Had Covid? You May Hold Key To Beating the VirusPutin Says Gas Exports to Be Halted If Ruble Payments Not MadeU.S. Criticizes India on Russia Talks as Lavrov Visits DelhiBiden Team Weighs a Massive Release of

Measuring and gauging the stock market's value is key to an investor’s strategy. Right now, it’s clear that the market is in the midst of a shift, that last year’s sustained run of gains has ended, that this year, which started with sharp losses and increased volatility, will be something different. Covering the market for investment firm Raymond James, strategist Tavis McCourt writes: “We are seeing a substantial rally in growth broadly in the last two weeks, and it is still unclear if this is

Shares of Qualcomm (NASDAQ: QCOM) were trading about 6% lower at 2 p.m. ET Friday after a JPMorgan analyst removed the semiconductor giant from its "analyst focus list," indicating that the firm no longer sees it as a top stock with meaningful upside from its current price.

Will we have enough to ‘live a simple life’ in retirement? Many other retirees wonder the same thing as you, and may be in similar financial circumstances where they’re able to pay the bills and have money saved in their retirement accounts. Your interest rate is fantastic, you’re capable of making the monthly payment from just your pension and Social Security without tapping into your 401(k) and you have so much of your home already paid off — all wins.

What happened Shares of semiconductor giant Nvidia (NASDAQ: NVDA) dropped in Friday afternoon trading, falling 2.9% through 12:55 p.m. ET. In the absence of any other news on Nvidia stock per se, it appears today's drop is tied to a Yahoo! Finance column that may have spooked investors.

DEEP DIVE It sure has been a wild ride for investors over the past few weeks, with the benchmark S&P 500 rising 10% from March 8 through March 30. But the broader stock market is still down for 2022.

Despite being one of the most recognizable wireless carriers in the U.S., AT&T stock has had a rough year. But it does have some perks.

The Chapter 11 petition was filed in response to an upcoming debt repayment obligation, Ruby said in a March 31 statement.

One key to market success is learning to recognize trends, overall directions that stocks are taking, and then riding those trends towards profitable returns. Sometimes, that task is easy; for instance, the five years from 2017 through the end of 2021 saw a prolonged run on generally increasing values. Sometimes, it’s more difficult; take a look at the charts for 2022 year-to-date and you’ll quickly see that there is no long-term direction of movement here. CNBC's Jim Cramer, however, believes t

The Pentagon has been providing daily updates on the Russian invasion of Ukraine and Ukraine's efforts to resist. The U.S. continues to see roughly 20% of the Russian forces that were arrayed against Kyiv repositioning away from the capital, the official said. "As these forces begin to reposition, the Ukrainians are moving against them," the official said.

Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") announces that its principal regulator, the Alberta Securities Commission, has granted a management cease trade order (the "MCTO").

Several ominous signs face the housing market. First, the average 30-year fixed-rate mortgage soared to a three-year high of 4.67% in the week ended March 31, according to housing agency Freddie Mac. The 10-year Treasury yield has climbed 91 basis points so far this year to 2.42%.

Investors in Nio (NYSE: NIO) have waited for a day like this for a long time now. On April 1, Nio said it delivered a record number of electric vehicles (EVs), totaling 25,768 units, in the quarter ending March. Although that's barely 3% higher compared to the last quarter, expectations were even more muted given the severe supply challenges facing automakers like Nio.

In this article, we discuss the 10 stocks to buy and hold for over 5 years according to Bill Gates. If you want to read about some more stocks in the portfolio of Bill Gates, go directly to Bill Gates Portfolio: 5 Stocks to Buy and Hold for Over 5 Years. Bill Gates stepped down […]

Canadian marijuana stocks were quiet after the House passed the MORE Act. So are any Canadian marijuana stocks buys now?

In this updated daily bar chart of TSLA, below, we can see that prices have had some problems in the $1,100-$1,250 area in the past. TSLA has surged quickly from late February on the order of around $300 and has stalled in the bottom end of this $1,000-$1,250 area. Trading volume does not look like it has expanded on this rally and the On-Balance-Volume (OBV) line has only made a slight rise.

QuantumScape (NYSE: QS) ended this week on a solid note, rising 15.8% through 2 p.m. ET Friday, according to data provided by S&P Global Market Intelligence. QuantumScape rocketed the afternoon of March 28 when an article from German business monthly, Manager Magazin, reported Porsche to be working with QuantumScape for solid-state batteries to power an electric version of its 911 sports car. Porsche is a Volkswagen (OTC: VWAGY) brand, and 911 a hugely popular car.

A tax on the wealthiest Americans has the potential to become a tax on the rest of the population, writes Thomas Hoenig.